Benzinga - by Lisa Levin, Benzinga Editor.
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform.
HubSpot
- The Trade: HubSpot, Inc. (NYSE: HUBS) Executive Chair Brian Halligan sold a total of 8,500 shares at an average price of $457.66. The insider received around $3.89 million from selling those shares.
- What’s Happening: Keybanc Capital Markets analyst Michael Turits reiterated the Overweight rating on HubSpot, lowering the price target to $593 from $660.
- What HubSpot Does: HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform.
VMware
- The Trade: VMware, Inc. (NYSE: VMW) EVP, Worldwide Sales Pierre Jean Brulard sold a total of 5,779 shares at an average price of $178.29. The insider received around $1.03 million from selling those shares.
- What’s Happening: VMware announced that the Government of Monaco has adopted a VMware Sovereign Cloud, provided by Monaco Cloud.
- What VMware Does: VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021.
- The Trade: Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Executive Chairman Jeffrey Leiden sold a total of 12,962 shares at an average price of $374.00. The insider received around $4.85 million from selling those shares.
- What’s Happening: Cantor Fitzgerald analyst Eric Schmidt reiterated Vertex Pharmaceuticals with an Overweight and maintained a $370 price target.
- What Vertex Pharmaceuticals Does: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.
- The Trade: Gilead Sciences, Inc. (NASDAQ: GILD) CFO Andrew D Dickinson sold a total of 5,000 shares at an average price of $80.00. The insider received around $400,017 from selling those shares.
- What’s Happening: Gilead Sciences announced new long-term real-world data from the BICSTaR study highlighting the safety and efficacy profile of Biktarvy.
- What Gilead Sciences Does: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C.
Check This Out: Tesla, AT&T And 3 Stocks To Watch Heading Into Thursday
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.